The science behind Regenicin cultured skin substitute is the use of a proprietary collagen sponge, biomedical polymer, to act as a connective agent in the skin generation process. The proprietary biomedical polymer is an important commercial product that could be developed for a variety of other applications outside of the production of Regenicin’s cultured skin substitute, NovaDerm®:
- repairing organs and tendons
- as a carrier for hormones or medicines
- as a protective healing agent for wounds
- as a scaffolding for regrowing organs
Banked Allogenic Cell Products can be developed for the biomedical polymer in products:
- for the treatment of chronic wounds
- for cosmetic or other topical testing, an alternative to animal testing
- for medical testing i.e. measuring the efficacy of transdermal medicine
- tissue banking to reduce shortages
Future Therapeutics
Regenicin™ continues to look towards the future with the development of other cell therapy technologies. We are excited to be able to bring those new developments to the commercial markets. As a company, Regenicin™ has a priority focus on developing future therapeutics in the following areas:
- diabetes
- chronic wounds, including ulcers
- adult stem cell therapies
- reconstructive surgery applications
- cosmetically elegant skin
- melanocyte concentration, pores & glands
- designed exclusively for the patient
